NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma
暂无分享,去创建一个
Kamran Ayub | Carissa A. Sanchez | Xiaohong Li | Patricia L. Blount | Carlo C Maley | C. Maley | P. Blount | B. Reid | P. Rabinovitch | T. Vaughan | R. Odze | P. Galipeau | C. Sanchez | Xiaohong Li | K. Ayub | Peter S Rabinovitch | Thomas L Vaughan | Robert D Odze | Patricia C Galipeau | Carissa A Sanchez | Brian J Reid | Patricia L Blount
[1] H. El‐Serag,et al. Meta-Analysis: Obesity and the Risk for Gastroesophageal Reflux Disease and Its Complications , 2005, Annals of Internal Medicine.
[2] A. Feinberg,et al. Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression , 1995, Nature Medicine.
[3] N. Sharpless,et al. INK4a/ARF: a multifunctional tumor suppressor locus. , 2005, Mutation research.
[4] B. Reid. p53 and neoplastic progression in barrett's esophagus , 2001, American Journal of Gastroenterology.
[5] D. Beer,et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. , 2000, Cancer research.
[6] Carissa A. Sanchez,et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.
[7] D. Forman,et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.
[8] P. O’Connell,et al. Genetic pattern of prostate cancer progression , 1999, International journal of cancer.
[9] David Neil Cooper,et al. Encyclopedia of the Human Genome , 2003 .
[10] M. Blaser,et al. Population attributable risks of esophageal and gastric cancers. , 2003, Journal of the National Cancer Institute.
[11] A. Sonnenberg,et al. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. , 2003, Gastroenterology.
[12] B. Reid,et al. Focus on Barrett's esophagus and esophageal adenocarcinoma. , 2004, Cancer cell.
[13] G. Falk,et al. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999, American Journal of Gastroenterology.
[14] F. Bosman,et al. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. , 2002, Gastroenterology.
[16] Carissa A. Sanchez,et al. Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.
[17] Susan Halabi,et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. , 2003, The New England journal of medicine.
[18] S. Lippman,et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment , 1996, Nature Medicine.
[19] E. Negri,et al. Aspirin use and cancers of the upper aerodigestive tract , 2003, British Journal of Cancer.
[20] Kenneth K Wang,et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. , 2002, Journal of the National Cancer Institute.
[21] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[22] Patricia L. Blount,et al. The Combination of Genetic Instability and Clonal Expansion Predicts Progression to Esophageal Adenocarcinoma , 2004, Cancer Research.
[23] R. Cestari,et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.
[24] K. Wada. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas. , 2002, Journal of hepato-biliary-pancreatic surgery.
[25] S. Lippman,et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M S Pepe,et al. Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.
[27] L. Bernstein,et al. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma , 2003, Cancer.
[28] G. Jenkins,et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma , 2002, The British journal of surgery.
[29] R. Sutton,et al. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus , 2003, Journal of gastroenterology and hepatology.
[30] B. Czerniak,et al. Genetic modeling of human urinary bladder carcinogenesis , 2000, Genes, chromosomes & cancer.
[31] T. Shankey,et al. Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.
[32] M. Gammon,et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. , 1998, Journal of the National Cancer Institute.
[33] W. Grady. Genetic testing for high-risk colon cancer patients. , 2003, Gastroenterology.
[34] Carissa A. Sanchez,et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[35] R. Haggitt,et al. Barrett's esophagus, dysplasia, and adenocarcinoma. , 1994, Human pathology.
[36] Patricia L. Blount,et al. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables , 2001, American Journal of Gastroenterology.
[37] D. Bostwick,et al. Independent origin of multiple foci of prostatic intraepithelial neoplasia , 1998, Cancer.
[38] P. Aló,et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. , 1998, Cytometry.
[39] B. Levin,et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.
[40] J. Soares,et al. Losses of Heterozygosity on Chromosomes 9p and 17p Are Frequent Events in Barrett’s Metaplasia Not Associated With Dysplasia or Adenocarcinoma , 2003, American Journal of Gastroenterology.
[41] M. Serrano,et al. Specific Contribution of p19ARF to Nitric Oxide-Dependent Apoptosis1 , 2006, The Journal of Immunology.
[42] Kenneth K Wang,et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. , 2002, Gastroenterology.
[43] Prateek Sharma,et al. p53 protein overexpression in low grade dysplasia (LGD) in barrett's esophagus: Immunohistochemical marker predictive of progression , 2001, American Journal of Gastroenterology.
[44] M. Sporn,et al. Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia , 2002 .
[45] C. Prives,et al. p53: puzzle and paradigm. , 1996, Genes & development.
[46] M. Feitelson,et al. Genetic mechanisms of hepatocarcinogenesis , 2002, Oncogene.
[47] S. Piantadosi,et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.
[48] M. Gammon,et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[49] I. Bièche,et al. Genetic pathways in the evolution of breast ductal carcinoma in situ , 2002, The Journal of pathology.
[50] J. Manson,et al. Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study , 1998, Annals of Internal Medicine.
[51] Kenneth K Wang,et al. Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.
[52] Patricia L. Blount,et al. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. , 2001, Cancer research.
[53] S. Baylin,et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3 , 1995, Nature Genetics.
[54] J. Epstein,et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. , 1999, International journal of cancer.
[55] L. Brown,et al. Epidemiologic trends in esophageal and gastric cancer in the United States. , 2002, Surgical oncology clinics of North America.
[56] B. Reid,et al. p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.
[57] Carissa A. Sanchez,et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression , 2001, American Journal of Gastroenterology.
[58] M. Gammon,et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. , 1997, Journal of the National Cancer Institute.
[59] D. Wong,et al. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. , 1997, Cancer research.
[60] E. Hawk,et al. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[61] R. Sampliner,et al. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus , 2002, American Journal of Gastroenterology.
[62] J. Minna,et al. Molecular genetic changes found in human lung cancer and its precursor lesions. , 1994, Cold Spring Harbor symposia on quantitative biology.
[63] M. Pepe,et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk , 2005, Oncogene.
[64] A. Tarnawski,et al. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action , 2002, American Journal of Gastroenterology.
[65] C. Sherr,et al. Principles of Tumor Suppression , 2004, Cell.
[66] C. Gutschow,et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males , 2001, Cancer.
[67] Leslie Bernstein,et al. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States) , 2001, Cancer Causes & Control.
[68] Mats Lindblad,et al. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study , 2005, Cancer Causes & Control.
[69] P. Laird,et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. , 2000, Cancer research.
[70] J. Califano,et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[72] Brian J. Reid,et al. Progressive Region-Specific De Novo Methylation of the p16 CpG Island in Primary Human Mammary Epithelial Cell Strains during Escape from M0 Growth Arrest , 1999, Molecular and Cellular Biology.
[73] S. Meltzer,et al. Biomarkers of Esophageal Adenocarcinoma and Barrett’s Esophagus , 2004, Cancer Research.
[74] Carissa A. Sanchez,et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[75] B. Reid,et al. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. , 1999, Genome research.
[76] M. Sporn,et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[77] W. Zoller,et al. [Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer]. , 2001, Zeitschrift fur Gastroenterologie.
[78] C. Williams,et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis , 1993, The British journal of surgery.
[79] B. Vogelstein,et al. Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[80] G. Beck,et al. A randomized trial of aspirin to prevent colorectal adenomas. , 2003, The New England journal of medicine.
[81] J. Goldblum,et al. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens , 2004, Modern Pathology.
[82] J. Lagergren,et al. Association between Body Mass and Adenocarcinoma of the Esophagus and Gastric Cardia , 1999, Annals of Internal Medicine.
[83] V. Moreno,et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995 , 2002, International journal of cancer.
[84] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[85] Rajnish A. Gupta,et al. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. , 2002, Journal of the National Cancer Institute.
[86] T. Iwama,et al. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[87] E. Hawk,et al. Chemoprevention in hereditary colorectal cancer syndromes , 1999, Cancer.
[88] C. Maley,et al. Natural selection in neoplastic progression of Barrett's esophagus. , 2005, Seminars in cancer biology.
[89] S. Piantadosi,et al. Poster 7: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization , 1996, Cancer research.
[90] Gary Longton,et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.
[91] T. Miyashita,et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. , 2004, Carcinogenesis.
[92] A. Giménez,et al. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with barrett's esophagus , 1998, Cancer.
[93] G. Lapertosa,et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. A prospective study , 2000 .
[94] D. Beer,et al. Selective inhibition of cyclooxygenase-2 inhibits growth and induces apoptosis in human esophageal adenocarcinoma cells , 2000 .
[95] S. Lippman,et al. Detection of chromosome instability of tissue fields at risk: In situ hybridization , 1996, Journal of cellular biochemistry. Supplement.
[96] L. Melton,et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota , 2001, Gut.
[97] A. Lindgren,et al. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia , 2000, International journal of cancer.
[98] J. Manson,et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. , 2005, JAMA.
[99] S. Lippman,et al. Predicting cancer development in oral leukoplakia: ten years of translational research. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[100] G. Lindberg,et al. Distribution of genetic variants in preneoplastic areas of colorectal tumours. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[101] R. López‐Ridaura,et al. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis , 2003, BMC Cancer.
[102] G. Triadafilopoulos,et al. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. , 2002, Gastroenterology.
[103] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[104] Patricia L. Blount,et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia , 2000, American Journal of Gastroenterology.
[105] H. Comber,et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. , 2006, Cancer research.
[106] Roland Eils,et al. Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data , 2004, International journal of cancer.
[107] Carissa A. Sanchez,et al. Selectively Advantageous Mutations and Hitchhikers in Neoplasms , 2004, Cancer Research.
[108] W. Hop,et al. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. , 1994, Gut.
[109] A. Gazdar,et al. Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. , 2002, Journal of the National Cancer Institute.
[110] N D Le,et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[111] K. Kerlikowske,et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. , 2003, Gastroenterology.
[112] A. Cameron,et al. Barrett's esophagus: age, prevalence, and extent of columnar epithelium. , 1992, Gastroenterology.
[113] J. Jansen,et al. Biomarkers in Barrett's esophagus (review). , 1998, International journal of oncology.
[114] Jing Yin,et al. Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus. , 1994, Cancer research.
[115] R. Sampliner,et al. Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. , 1989, Gastroenterology.
[116] S. Lippman,et al. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[117] D. Forman,et al. TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort , 2006, Gut.
[118] Carissa A. Sanchez,et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. , 2000, Journal of the National Cancer Institute.
[119] Carissa A. Sanchez,et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. , 2005, The Lancet. Oncology.
[120] M. King,et al. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.
[121] S. Piantadosi,et al. Primary chemoprevention of familial adenomatous polyposis with sulindac , 2002 .